0000000000770817

AUTHOR

Nicola Ricco

showing 2 related works from this author

Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network

2020

Objective. To analyze the potential role of colchicine monotherapy in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) in terms of control of clinical and laboratory manifestations. Methods. Patients with TRAPS treated with colchicine monotherapy were retrospectively enrolled; demographic, clinical and therapeutic data were collected and statistically analysed after having clustered patients according to different times at disease onset, penetrance of mutations, dosage of colchicine, and different disease manifestations. Results. 24 patients (14 males; 15 with pediatric disease onset) treated with colchicine monotherapy were enrolled. Colchicine resulted in …

Male0301 basic medicineEye DiseasesTRAPSColchicineAIDA NetworkGene mutationGastroenterologyReceptors Tumor Necrosis Factorchemistry.chemical_compoundSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineReceptorsPathologyRB1-214ColchicineAge of OnsetYoung adultChildAmyloidosisAmyloidosisSyndromeMiddle AgedColchicine tumor necrosis factor TRAPSInflamacióPenetrancePhenotypeChild PreschoolFemaleJoint DiseasesResearch ArticleAdultRiskmedicine.medical_specialtyAdolescentFeverArticle SubjectImmunologyAdolescent; Adult; Age of Onset; Amyloidosis; Child; Child Preschool; Colchicine; Exanthema; Eye Diseases; Female; Fever; Humans; Joint Diseases; Male; Middle Aged; Mutation; Myalgia; Phenotype; Receptors Tumor Necrosis Factor; Retrospective Studies; Risk; Syndrome; Young AdultLower riskYoung Adult03 medical and health sciencesInternal medicinemedicineHumansPreschoolRetrospective StudiesInflammation030203 arthritis & rheumatologybusiness.industryTRAPSRetrospective cohort studyMyalgiaCell BiologyExanthemamedicine.disease030104 developmental biologychemistryMutationAge of onsetColchicineTumor Necrosis FactorbusinessMediators of Inflammation
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct